natgillin/translations-raw huggingface dataset:
If not established on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
Ako za bolesnicu nije utvrđena djelotvorna kontracepcija, bolesnicu se mora uputiti odgovarajuće osposobljenom zdravstvenom radniku za savjet o kontracepciji kako bi je mogla početi primjenjivati.
Based on in vitro data, pomalidomide is not an inhibitor or inducer of cytochrome P-450 isoenzymes, and does not inhibit any drug transporters that were studied.
Na temelju podataka in vitro, pomalidomid nije ni inhibitor niti induktor izoenzima citokroma P-450 i ne inhibira nijedan od prijenosnika koji su bili ispitani.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza oznake „EXP“.
The Direct Healthcare Professional Communication shall consist of two parts:
Pisma zdravstvenim radnicima sastojat će se od dva dijela:
Co-administration of pomalidomide with the strong CYP3A4/5 and P-gp inhibitor ketoconazole, or the strong CYP3A4/5 inducer carbamazepine, had no clinically relevant effect on exposure to pomalidomide.
Istodobna primjena pomalidomida s jakim inhibitorom CYP3A4/5 i P-gp-a ketokonazolom, ili jakim induktorom CYP3A4/5 karbamazepinom, nije imala klinički važnog učinka na izloženost pomalidomidu.
What Imnovid contains
Što Imnovid sadrži
Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.
Bolesnike treba upozoriti da nikada ne daju svoj lijek drugoj osobi te da sve neiskorištene kapsule vrate svom ljekarniku nakon završetka liječenja.
Details of the PPP should be agreed with the National Competent Authorities in each Member State and put in place prior to the marketing of the product.
Pojedinosti Programa prevencije trudnoće treba dogovoriti s nadležnim državnim tijelima u svakoj državi članici i isti ustrojiti prije stavljanja lijeka u promet.
• Safety advice for women of childbearing potential o The need to avoid foetal exposure o Description of the PPP o Need for effective contraception (even if woman has amenorrhoea) and definition of effective contraception
• Sigurnosni savjeti za žene u reproduktivnoj dobi o potreba za izbjegavanjem fetalne izloženosti o opis Programa prevencije trudnoće o potreba za djelotvornom kontracepcijom (čak i ako žena ima amenoreju) i definicija djelotvorne kontracepcije
The efficacy of contraceptive steroids may be reduced during cotreatment with dexamethasone (see section 4.5).
Djelotvornost steroidnih kontraceptiva može biti umanjena tijekom istodobnog liječenja deksametazonom (vidjeti dio 4.5).
However, if you are over 75,
Međutim, ako imate više od
Approximately 70% of patients were refractory to lenalidomide (71.2% in Pom+Btz+LD-Dex, 68.7 % in Btz+LD-Dex).
Približno 70% bolesnika bilo je refraktorno na lenalidomid (71,2% u skupini Pom+Btz+LD-Dex, 68,7% u skupini Btz+LD-Dex).
Slight reduction in maternal body weight gain, significant reduction in triglycerides, and significant dec rease in absolute and relative spleen weights were observed at 100 and 250 mg/kg/day.
Blago smanjeno povećanje tjelesne težine majki, značajno sniženje razine triglicerida i značajno snižene apsolutne i relativne težine slezene bili su opaženi pri dozama od 100 i 250 mg/kg na dan.
Add H2 blocker or equivalent and resume at one dose level lower than previous dose.
Dodati H2 blokator ili ekvivalent i nastaviti liječenje u dozi koja je za jednu razinu niža od prethodne.
• Medroxyprogesterone acetate depot
• depo preparat medroksiprogesteron acetata
The most commonly reported serious adverse reaction was pneumonia (9.3%).
Najčešće zabilježena ozbiljna nuspojava bila je pneumonija (9,3%).
This condition is called tumour lysis syndrome.
To se stanje naziva sindrom lize tumora.
The p-value is based on a stratified log-rank test.
d p-vrijednost temelji se na nestratificiranom log-rang testu
In peripheral tissues, pomalidomide was preferentially taken up by tumors with apparent peripheral distribution clearance (Q/F) and apparent peripheral volume of distribution (V3/F) 3.7-fold and 8-fold higher, respectively, than that of healthy subjects.
U perifernim tkivima pomalidomid su preuzimali prvenstveno tumori s prividnim klirensom periferne distribucije (Q/F) 3,7 puta i prividnim perifernim volumenom distribucije (V3/F) 8 puta višim nego što je to bilo u zdravih ispitanika.
Peripheral neuropathy led to discontinuation of bortezomib in approximately 12.9% of patients, pomalidomide in 1.8% and dexamethasone in 2.2 - 8.9% of patients, respectively.
Periferna neuropatija dovela je prestanka primjene bortezomiba u približno 12,9% bolesnika, pomalidomida u 1,8% i deksametazona u 2,2 - 8,9% bolesnika.
• Prior to launch, all doctors who intend to prescribe pomalidomide and all pharmacists who may dispense pomalidomide receive a Direct Healthcare Professional Communication as described below.
• prije stavljanja lijeka na tržište svi liječnici koji namjeravaju propisivati pomalidomid i svi ljekarnici koji bi mogli izdavati pomalidomid primiti priopćenje zdravstvenim radnicima kako je to opisano u nastavku;
• She understands the need and accepts to undergo pregnancy testing at least every 4 weeks except in case of confirmed tubal sterilisation
• shvaća potrebu i prihvaća podvrgnuti se testiranju na trudnoću najmanje svaka 4 tjedna osim u slučaju potvrđenog podvezivanja jajovoda
If you are uncertain whether any of the conditions above apply to you, talk to your doctor, pharmacist or nurse before taking Imnovid.
Ako niste sigurni odnosi li se bilo što od gore navedenoga na Vas, obratite se svojemu liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Imnovid.
CYP dependent metabolites account for approximately 43% of the total excreted radioactivity, while nonCYP dependent hydrolytic metabolites account for 25%, and excretion of unchanged pomalidomide accounted for 10% (2% in urine and 8% in faeces).
Metaboliti ovisni o CYP čine približno 43% ukupno izlučene radioaktivnosti, metaboliti koji ne ovise o CYP čine 25%, dok je izlučivanje neizmijenjenog pomalidomida činilo 10% (2% u mokraći i 8% u stolici).
Following multiple doses, pomalidomide has an accumulation ratio of 27 to 31% on AUC.
Nakon višekratnih doza, omjer nakupljanja pomalidomida u AUC-u iznosi od 27 do 31%.
Patients > 75 years of age started treatment with 20 mg dexamethasone.
Bolesnici u dobi od >75 godina počeli su liječenje dozom od 20 mg deksametazona.
Patients should be monitored for haematological adverse reactions, especially neutropenia.
Bolesnike valja nadzirati zbog hematoloških nuspojava, osobito neutropenije.
Prescriptions for women of childbearing potential can be for a maximum duration of 4 weeks, and prescriptions for all other patients can be for a maximum duration of 12 weeks.
Ženama reproduktivne dobi recept može vrijediti najviše 4 tjedna, a svim drugim bolesnicima najviše 12 tjedana.
The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.
Programa prevencije trudnoće, osim ako postoji pouzdan dokaz da bolesnik nije u reproduktivnoj dobi.
Appropriate caution should be exercised when considering the treatment of such patients with pomalidomide, including periodic monitoring for signs or symptoms of cardiac events.
Kada se za takve bolesnike razmatra mogućnost liječenja pomalidomidom, potreban je odgovarajući oprez uključujući povremeno praćenje znakova ili simptoma srčanih događaja.
Insertion of copper-releasing intrauterine devices is not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with severe neutropenia or severe thrombocytopenia.
Intrauterini ulošci koji oslobađaju bakar općenito se ne preporučuju zbog mogućih rizika od infekcije u vrijeme umetanja te gubitka krvi menstrualnim krvarenjem, što može ugroziti bolesnicu s teškom neutropenijom ili teškom trombocitopenijom.
• A fall in the number of red and white blood cells and platelets at the same time (pancytopenia), which will make you more prone to bleeding and bruising.
• istodobno smanjenje broja crvenih i bijelih krvnih stanica te krvnih pločica (pancitopenija) zbog čega ćete biti skloniji krvarenju i nastanku modrica.
The majority of patients were male (59%) and white (79%); the median age for the overall population was 64 years (min, max: 35, 87 years).
Većina bolesnika bili su muškarci (59%) i bijelci (79%); medijan dobi u populaciji bio je 64 godine (raspon 35 - 87 godina).
Interrupt dose until muscle weakness ≤ Grade 1.
Prekinuti liječenje dok se ne postigne mišićna slabost ≤1. stupnja.
Pomalidomide is structurally related to thalidomide.
Pomalidomid je strukturno srodan talidomidu.
To initiate a new cycle of pomalidomide, the neutrophil count must be  1 x 109/l and the platelet count must be  50 x 109/l.
Da bi se moglo započeti s novim ciklusom terapije pomalidomidom, broj neutrofila mora biti ≥1 x 109/l, a broj trombocita ≥50 x 109/l.
Cardiac events, including congestive cardiac failure, pulmonary oedema and atrial fibrillation (see section 4.8), have been reported, mainly in patients with pre-existing cardiac disease or cardiac risk factors.
Srčani događaji, uključujući kongestivno zatajenje srca, edem pluća i fibrilaciju atrija (vidjeti dio 4.8), zabilježeni su uglavnom u bolesnika s postojećom bolešću srca ili s čimbenicima rizika za srčanu bolest.
Pomalidomide is not anticipated to cause clinically relevant pharmacokinetic drug-drug interactions due to P450 isoenzyme inhibition or induction or transporter inhibition when co-administered with substrates of these enzymes or transporters.
Ne očekuje se da će pomalidomid prouzročiti klinički važne farmakokinetičke interakcije lijekova zbog inhibicije ili indukcije izoenzima P450 ili inhibicije prijenosnika kad se primjenjuje istodobno sa supstratima tih enzima ili prijenosnika.
Stop taking Imnovid and see a doctor straight away if you notice any of the serious side effects listed above - you may need urgent medical treatment.
Prestanite uzimati Imnovid i odmah se obratite liječniku ako opazite neku od prethodno navedenih ozbiljnih nuspojava - možda Vam je potrebna hitna medicinska pomoć.
Interrupt pomalidomide treatment.
Prekinuti liječenje pomalidomidom.
• Imnovid and dexamethasone are taken in ‘treatment cycles'.
• Imnovid i deksametazon uzimaju se u „ciklusima liječenja“.
Pomalidomide enhances T cell- and natural killer (NK) cell-mediated immunity and inhibits production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes.
Natural Killer, NK) i inhibira stvaranje proinflamatornih citokina (npr. TNF-α i IL-6) u monocitima.
Patients receiving pomalidomide either in combination with bortezomib and dexamethasone or in combination with dexamethasone have developed venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and cerebrovascular accident).
U bolesnika koji primaju pomalidomid u kombinaciji s bortezomibom i deksametazonom ili u kombinaciji s deksametazonom, nastali su venski tromboembolijski događaji (pretežno duboke venske tromboze i plućne embolije) te arterijski trombotski događaji (infarkt miokarda i cerebrovaskularni akcident).
Based on population PK analysis using a two-compartment model, healthy subjects and MM patients had comparable apparent clearance (CL/F) and apparent central volume of distribution (V2/F).
Na temelju populacijske farmakokinetičke analize primjenom modela s dva odjeljka, zdravi ispitanici i bolesnici s multiplim mijelomom imali su sličan prividni klirens (CL/F) i prividni središnji volumen distribucije (V2/F).
Pack size of 14 or 21 capsules.
Pakiranje sadrži 14 ili 21 kapsulu.
PFS (months) Mediana time (95% CI) b HR c (95% CI), p-valued ORR, n (%) sCR
PFS (mjeseci) Medijana (95% CI)b HRc (95% CI), p-vrijednostd ORR, n (%) sCR
Coadministration with a high-fat and high-calorie meal slows the rate of absorption, decreasing mean plasma Cmax by approximately 27%, but has minimal effect on the overall extent of absorption with an 8% decrease in mean AUC.
Istodobna primjena punomasnih i visokokaloričnih obroka kod zdravih dobrovoljaca usporava brzinu apsorpcije smanjujući srednju vrijednost Cmax u plazmi za približno 27%, ali minimalno utječe na ukupni opseg apsorpcije uz 8%-tno smanjenje srednje vrijednosti AUC-a.
A total of 455 patients were enrolled in the study: 302 in the Pom+LD-Dex arm and 153 in the HD-Dex arm.
Ukupno je 455 bolesnika bilo uključeno u ispitivanje: 302 u skupinu koja je primala Pom+LD-Dex i 153 u skupinu koja je primala HD-Dex.
If powder from a broken Imnovid capsule makes contact with the skin, wash the skin immediately and thoroughly with soap and water.
Ako prašak iz razlomljene kapsule Imnovida dođe u dodir s kožom, odmah temeljito isperite kožu vodom i sapunom.
Caution should be exercised when pomalidomide in combination with dexamethasone is used in patients previously infected with HBV, including patients who are anti-HBc positive but HBsAg negative.
Potreban je oprez kada se pomalidomid u kombinaciji s deksametazonom primjenjuje u bolesnika koji su prije bili zaraženi virusom hepatitisa B, uključujući bolesnike koji su anti-HBc pozitivni, ali HBsAg negativni.
For women of childbearing potential, pomalidomide is contraindicated unless all of the following are met:
Pomalidomid je kontraindiciran za žene u reproduktivnoj dobi, osim ako se ispune svi sljedeći zahtjevi:
At the end of the treatment you should return all unused capsules to the pharmacist.
Na kraju liječenja trebate vratiti sve nepotrošene kapsule ljekarniku.
The patient card shall contain the following elements:
Kartica za bolesnika sadržavat će sljedeće elemente:
A total of 226 (74.8%) of the Pom + LD-Dex patients and 95 (62.1%) of the HD-Dex patients were alive as of the cutoff date (07 Sep 2012).
Ukupno je 226 (74,8%) bolesnika koji su primali Pom+LD-Dex i 95 (62,1%) bolesnika koji su primali HD-Dex bilo živo do datuma prestanka prikupljanja podataka (07. rujna 2012.).
Fatigue, depressed level of consciousness, confusion, and dizziness have been reported with the use of pomalidomide.
Umor, snižena razina svijesti, konfuzija i omaglica prijavljeni su uz primjenu pomalidomida.
Some people feel tired, dizzy, faint, confused or less alert when taking Imnovid.
Neke osobe osjećaju umor, omaglicu, nesvjesticu, smetenost ili smanjenu pozornost dok uzimaju Imnovid.
For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.
Bolesnicima s pozitivnim testom na infekciju virusom hepatitisa B preporučuje se da zatraže savjet liječnika s iskustvom u liječenju hepatitisa B.
On haemodialysis days, patients should take their pomalidomide dose following haemodialysis.
U dane kad je primijenjena hemodijaliza, bolesnici trebaju uzeti svoju dozu pomalidomida nakon postupka hemodijalize.
• High blood levels of uric acid, which may cause a form of arthritis called gout.
• visoke razine mokraćne kiseline u krvi, što može prouzročiti oblik artritisa pod nazivom giht
Infections led to pomalidomide discontinuation in 2.0-2.9% of patients.
Infekcije su dovele do prestanka primjene pomalidomida u 2,0 - 2,9% bolesnika.
At 250 mg/kg/day, fetal malformations included limb anomalies (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia); moderate dilation of the lateral ventricle in the brain; abnormal placement of the right subclavian artery; absent intermediate lobe in the lungs; low-set kidney; altered liver morphology; incompletely or not ossified pelvis; an increased average for supernumerary thoracic ribs and a reduced average for ossified tarsals.
Pri dozi od 250 mg/kg na dan, fetalne malformacije uključivale su anomalije udova (savijeni i/ili rotirani prednji i stražnji udovi, nespojeni ili odsutni prst) i s time povezane malformacije kostura (neosificirane metakarpalne kosti, neporavnate falangealne i metakarpalne kosti, odsutnost prsta, neosificirane falange i kratka neosificirana ili svijena tibija), umjereno proširena lateralna moždana komora; abnormalna lokalizacija desne arterije supklavije; odsutnost srednjeg režnja pluća; nisko postavljen bubreg; promijenjena morfologija jetre; nepotpuno osificirane ili neosificirane zdjelične kosti; povišen prosječni broj prekobrojnih torakalnih rebara i smanjen prosječni broj osificiranih tarzalnih kostiju.
Haemorrhagic disorders have been reported with pomalidomide, especially in patients with risk factors such as concomitant medicinal products that increase susceptibility to bleeding.
Hemoragijski poremećaji zabilježeni su uz primjenu pomalidomida, osobito u bolesnika s čimbenicima rizika kao što je istodobna primjena lijekova koji povećavaju sklonost krvarenju.
Specifically, pomalidomide inhibits proliferation and induces apoptosis of haematopoietic tumour cells.
Konkretno, pomalidomid inhibira proliferaciju i inducira apoptozu tumorskih stanica.
At 100 and 250 mg/kg/day, there were slight increases in post-implantation loss and slight decreases in fetal body weights.
Pri dozama od 100 i 250 mg/kg na dan, opaženo je blago povećanje postimplantacijskih gubitaka i blago sniženje fetalne tjelesne težine.
(E172), erythrosin (E127) and white ink.
(E172), eritrozin (E127) i bijelu tintu.
Drug Reaction with Eosinophilia and Systemic Symptoms Toxic Epidermal Necrolysis Stevens-Johnson Syndrome
Nepoznato reakcija na lijek s eozinofilijom i sistemskim simptomima toksična epidermalna nekroliza Stevens-Johnsonov sindrom
In rabbits, pomalidomide at dosages ranging from 10 to 250 mg/kg produced embryo-foetal developmental malforma tions.
Kod kunića, pomalidomid je u dozama u rasponu od 10 do 250 mg/kg izazvao embriofetalne razvojne malformacije.
• Levonorgestrel-releasing intrauterine system
• intrauterini uložak s otpuštanjem levonorgestrela
In the 9-month study in monkeys with doses of 0.05, 0.1, and 1 mg/kg/day, morbidity and early euthanasia of 6 animals were observed at the dose of 1 mg/kg/day and were attributed to immunosuppressive effects (staphylococcal infection, decreased peripheral blood lymphocytes, chronic inflammation of the large intestine, histologic lymphoid depletion, and hypocellularity of bone marrow) at high exposures of pomalidomide (15-fold exposure ratio relative to a 4 mg clinical dose).
Tijekom 9-mjesečnog ispitivanja na majmunima pomoću doza od 0,05, 0,1 i 1 mg/kg na dan, morbiditet i rana eutanazija 6 životinja bila je opažena pri dozi od 1 mg/kg na dan i pripisana imunosupresivnim učincima (stafilokoknoj infekciji, sniženom broju limfocita u perifernoj krvi, kroničnoj upali debelog crijeva, histološkoj lifmoidnoj depleciji i hipocelularnosti koštane srži) pri visokoj izloženosti pomalidomidu (15 puta veći omjer izloženosti u odnosu na kliničku dozu od 4 mg).
For patients >75 years of age, the starting dose of dexamethasone is:
>75 godina, početna doza deksametazona je:
The mean changes in exposure to pomalidomide in each of these renal impairment groups are not of a magnitude that requires dosage adjustments.
Srednje vrijednosti promjene izloženosti pomalidomidu u svakoj od tih skupina s oštećenjem funkcije bubrega nisu takvog opsega da bi zahtijevale prilagodbe doze.
Peripheral neuropathy occurred in 12.3% of patients (1.0% Grade 3 or 4).
Periferna neuropatija pojavila se u 12,3% bolesnika (1,0% 3. ili 4. stupnja).
C] -pomalidomide (2 mg) to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and faeces, respectively, with approximately 2% and 8% of the dosed radiocarbon eliminated as pomalidomide in urine and faeces.
C]-pomalidomida (2 mg) u zdravih ispitanika, približno se 73% radioaktivne doze eliminiralo mokraćom, a 15% stolicom, s time da se približno 2% doze radioaktivnog izotopa ugljika eliminiralo kao pomalidomid mokraćom, a 8% stolicom.
The median duration of treatment was 8.8 months (12 treatment cycles) in the Pom+Btz+LD-Dex arm and 4.9 months (7 treament cycles) in the Btz+LD-Dex arm.
Medijan trajanja liječenja bio je 8,8 mjeseci (12 ciklusa liječenja) u skupini Pom+Btz+LD-Dex i 4,9 mjeseci (7 ciklusa liječenja) u skupini Btz+LD-Dex.
Pomalidomide has a mean apparent volume of distribution (Vd/F) between 62 and 138 L at steady state.
Pomalidomid ima srednji prividni volumen raspodjele (Vd/F) između 62 i 138 litara u stanju dinamičke ravnoteže.
• Bleeding or bruising without a cause, including nosebleeds and bleeding from the bowels or stomach (due to effects on blood cells called ‘platelets').
• krvarenje ili nastanak modrica bez uzroka, uključujući krvarenje iz nosa i krvarenje iz crijeva ili želuca (zbog učinaka na krvne pločice koje se zovu i „trombociti“)
Day IMN BOR DEX
Dan IMN BOR DEKS
Pomalidomide crossed the placenta and was detected in foetal blood following administration to pregnant rabbits, see section 5.3.
Pomalidomid je prelazio placentu i bio je detektiran u fetalnoj krvni nakon primjene skotnim ženkama kunića, vidjeti dio 5.3.
• She should be capable of complying with effective contraceptive measures
• žena mora biti u stanju pridržavati se mjera djelotvorne kontracepcije
You should not donate blood during treatment and for 7 days after the end of treatment.
Ne smijete darivati krv za vrijeme liječenja i 7 dana nakon završetka liječenja.
Second primary malignancies, such as non-melanoma skin cancer, have been reported in patients receiving pomalidomide (see section 4.8).
Druge primarne maligne bolesti, primjerice nemelanomski rak kože, zabilježene su kod bolesnika koji primaju pomalidomid (vidjeti dio 4.8).
It is not known if Imnovid passes into human breast milk.
Nije poznato prelazi li Imnovid u majčino mlijeko.
PFS was evaluated in several relevant subgroups: gender, race, ECOG performance status, stratification factors (age, disease population, prior anti-myeloma therapies [2, > 2]), selected parameters of prognostic significance (baseline beta-2 microglobulin level, baseline albumin levels, baseline renal impairment, and cytogenetic risk), and exposure and refractoriness to prior anti-myeloma therapies.
PFS je procijenjen u nekoliko važnih podskupina: po spolu, rasi, ECOG statusu, stratifikacijskim čimbenicima (dob, populacija s bolešću, prethodne antimijelomske terapije [2, >2]), odabranim prognostički značajnim parametrima (početna razina beta-2 mikroglobulina, početna razina albumina, početno oštećenje bubrega i citogenetski rizik) te izloženosti i refraktornosti prije antimijelomskih terapija.
• Decreased ability to move or feel (sensation) in your hands, arms, feet and legs because of nerve damage (peripheral sensorimotor neuropathy).
• smanjena sposobnost pomicanja ili gubitak osjeta u rukama, šakama, nogama i stopalima zbog oštećenja živca (periferna senzomotorna neuropatija)
• Imnovid, bortezomib and dexamethasone are taken in ‘treatment cycles'.
• Imnovid, bortezomib i deksametazon uzimaju se u „ciklusima liječenja“.
The recommended starting dose of bortezomib is 1.3 mg/m2 intravenous or subcutaneous once daily, on the days shown in Table 1.
Preporučena početna doza bortezomiba iznosi 1,3 mg/m2 intravenski ili supkutano jedanput na dan, a primjenjuje se na dane kako je označeno u tablici 1.
In vivo, pomalidomide therapy led to reduction in the levels of Ikaros in patients with relapsed lenalidomiderefractory multiple myeloma.
Terapija pomalidomidom dovela je in vivo do smanjenja razina Ikarosa u bolesnika s recidivom multiplog mijeloma refraktornog na lenalidomid.
• Shortness of breath (from serious chest infection, inflammation of the lung, heart failure or blood clot).
• nedostatak zraka (zbog ozbiljne infekcije pluća, upale pluća, zatajenja srca ili krvnog ugruška)